Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending September 16, 2018
Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019
Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055
Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022
High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.
Feds move to streamline oversight of gene therapy, Collins FS and Gottlieb S. N Engl J Med. doi: 10.1056/NEJMp1810628
Must reads for theWeek ending September 16, 2018
Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019
Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055
Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022
High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.
Feds move to streamline oversight of gene therapy, Collins FS and Gottlieb S. N Engl J Med. doi: 10.1056/NEJMp1810628
Must reads for theWeek ending September 9, 2018
Bladder cancer: Dose-dense MVAC yields improved response, survival, Peyton CC et al. JAMA Oncology. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3542.
Oncology studies lack full disclosure of industry payments, Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.
Methotrexate escalation in T-cell ALL, Winter SS et al. J Clin Oncol. 2018 Aug 23. doi: 10.1200/JCO.2018.77.7250.
RELEVANCE data sheds light on follicular lymphoma treatment, Morschhauser F et al. N Engl J Med. 2018;379:934-47.
TYK2 could be a drug target in ALCL, Prutsch N et al. Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0239-1.
Must reads for theWeek ending September 2, 2018
Refractory esophagogastric cancer: Nivolumab plus ipilimumab ups response rate , Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.
Baseline steroid use may decrease efficacy of checkpoint inhibitors, Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.
Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.
Nivolumab plus ipilimumab ups survival in melanoma patients with brain mets, Tawbi HA et al. N Engl J Med. 2018 Aug 23. doi: 10.1056/NEJMoa1805453
NSCLC: Capmatinib plus gefitinib overcomes EGFR resistance , Wu et al. J Clin Oncol. 2018 Aug 29. doi: 10.1200/JCO.2018.77.7326.
Must reads for theWeek ending August 26, 2018
Prognostic factors in PRCC identified, Polifka I et al. Hum Pathol. 2018 Aug 16. doi: 10.1016/j.humpath.2018.08.006.
Rituximab maintenance leads to better MCL outcomes, Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.
CBC outperforms D-dimer in predicting DVT, The annual meeting of the American College of Physicians
Multidisciplinary care shortens hospital stay in sickle cell disease, Annual symposium of the Foundation for Sickle Cell Disease Research
CAR T signaling strength analyzed in preclinical study, Salter AI et al., Sci Signal. 2018 Aug 21;11. pii:eaat6753.